Option chain shows key data for WISeKey Intl Holding's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for WISeKey Intl Holding.

WISeKey Intl Holding (OTC:WSKEF) Stock, Option Chain

WISeKey International Holding Ltd is a cybersecurity company focused on delivering integrated security solutions for the Internet of Things and digital identity ecosystems. It integrates secure semiconductors, cybersecurity software, and a globally recognized Root of Trust (RoT) into products and services that protect users, devices, data and transactions in the internet-connected world. It has two business segments. The IoT segment, which is the key revenue driver, generates revenue from the sale of semiconductor's secure chips. The mPKI segment generates revenues from Digital Certificates, It derives maximum revenue from IoT segment.

News

Movers & Shakers

Intraday Update

Markets

Movers

Trading Ideas

General

AAEEF

AAPT

ACMUY

AEMD

AGTK

AKRX

AMNL

BGOUF

BKPPF

BRTX

BYZN

CANSF

CANWF

CBGZF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CBYDF

CCNCF

CNBX

CPAH

CPNFF

CRCW

CXRXF

DECN

DECXF

DLOC

DXBRF

EANRF

EKSO

ELGX

ELLXF

FPAFY

FRLF

FTFT

GALT

GCFB

GTCH

GTII

GWRRF

HIPH

HPIL

INNT

IRNC

JXMNF

KMPH

KRKR

LESAF

LGDDF

LTMCF

MAOMF

MAYS

MGEN

MITO

MLXEF

MMJJF

NABIF

NAKD

NMHLY

NOSOF

NSUPF

NXTTF

OIBRQ

OTEL

PHMB

PRVU

PTOTF

QMC QUANTUM MINERALS CORP by QMC Quantum Minerals Corp.

QMCQF

RGRNF

RMIOF

ROYL

RPNMF

SEED

SZCRF

TCON

THTX

TOMDF

TOWER ONE WIRE ORD (A) by Tower One Wireless Corp

TOWTF

UDIRF

UFMG

VLRX

WATT

WCVC

WDDMF

WECFF

WLSI

WSKEF

ZSAN

MGXRF

Stocks That Hit 52-Week Lows On Friday

ABWN

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

AQMS

Alterity Therapeutics Limited - American Depositary Shares

ATHE

ATHX

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

ATYG

BGFT

BLOZF

BOIRF

BWLVF

CBRI

CCGN

CHMR

CMGHF

COCP

CORV

COTE

CSPUF

DVLY

DYLLF

ECOR

FERL

FINCANNA CAPITAL CORP by Fincanna Capital Corp.

FNNZF

FUAPF

FVGCF

FVVSF

GGBXF

GLBS

GTBP

GURE

HEMP

HESG

HGEN

HKTTF

HUABF

HVBTF

ICABY

IPSEY

ISIG

IWSY

KINS

LATF

LFUGF

LFUGY

MCET

MDIN

MGXMF

MIST

MOAEF

NHNKY

NIMU

OCANF

OGDCF

OLVRF

PARNF

PHAT

PHTCF

PHUN

PMSO

PRTR

PSIX

QBAN

QEGY

QOIL

RETC

RKAGY

RTTR

RVLT

SEEK

SFEG

SING

SNNAF

SPVNF

SUIC

TBEV

TGIFF

TLGN

TLRY

TOCA

TRPX

TWMC

UBQU

UVSE

VFRM

VGGOF

VREOF

VVCIF

WHITF

ICC INTL CANNABIS CORP by ICC Intl Cannabis Corp.

WLDCF

Stocks That Hit 52-Week Lows On Wednesday

WISEKEY INTL HLDGS LTD by WISeKey International Holding Ltd.

WISeKey International Holding Ltd

Stifel initiated coverage on Cytokinetics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>), noting the company&#8217;s catalyst rich one to two years.
The M&amp;A speculation ramped up in early 2024 after the company released SEQUOIA-HCM Phase 3 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36413624/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-pot" target="_blank" rel="noreferrer noopener">trial data of&nbsp;aficamten</a> in December 2023. However, last year,&nbsp;Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) decided to step back from pursuing <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36616494/cytokinetics-heart-drug-is-a-multi-billion-dollar-opportunity-by-2032-despite-novar" target="_blank" rel="noreferrer noopener">the&nbsp;Cytokinetics deal</a>.
Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) also all popped up as potential suitors, though the stock faded from there as a deal never materialized.
Also Read: <a href="https://www.benzinga.com/general/biotech/24/09/40778617/cytokinetics-sets-stage-for-mid-stage-study-for-heart-failure-drug-after-encouraging-data-from-ph" target="_blank" rel="noreferrer noopener">Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study</a>
Cytokinetics has fallen out of favor with investors after a turbulent start to 2024, marked by a controversial Royalty Pharma Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) deal and no <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38992589/heart-disease-focused-cytokinetics-operations-are-on-track-despite-acquisition-unce" target="_blank" rel="noreferrer noopener">mergers or acquisitions</a>.
Investors poorly received the structure of the Royalty Pharma deal at the time, and it continues to be a concern for many even today.
Stifel has initiated coverage with a Buy rating and a <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast of $80</a>. However, the outlook appears promising, with its valuation adjusted and several catalysts expected over the next 12+ months.
Stifel analyst James Condulis writes Cytokinetics&#8217; aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy (oHCM) market.
As the rollout of Bristol Myers Squibb Co&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Camzyos mavacamten continues, some concerns remain about its potential in treating obstructive hypertrophic cardiomyopathy (oHCM).
While the initial launch is not seen as a negative sign for mavacamten&#8217;s potential, its Risk Evaluation and Mitigation Strategy (REMS) is a barrier to fully unlocking the market.
Cytokinetics appears well-positioned to capitalize on Bristol Myers&#8217; groundwork with its second-to-market drug, aficamten, which is expected to have a best-in-class profile. There is a strong case for aficamten to secure a differentiated REMS, potentially including six-month echocardiograms (Q6M echos) as a standard.
Under conservative assumptions, aficamten could drive the U.S. oHCM market to approximately $3 billion.
Looking ahead to 2025 and 2026, Phase 3 nHCM data and early findings for HFpEF could present new opportunities. Although mergers and acquisitions are not a key focus, potential strategic interest could bring unexpected benefits.
Price Action: CYTK stock is up 3.45% at $47.40 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43131221/halliburton-faces-mixed-q4-with-north-american-weakness-but-global-gains-and-cash-flow-bolster-optimism" target="_blank" rel="noreferrer noopener">Halliburton Faces Mixed Q4 With North American Weakness, But Global Gains And Cash Flow Bolster Optimism</a></li>
</ul>

Analyst Color

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Comments

WISeKey Intl Holding

WISeKey Intl Holding (WSKEF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga